Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Maravai LifeSciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Maravai LifeSciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$25.26M. For fiscal 2025 it was -$57.57M, down 871.2% from the year before. The highest annual figure on record is $535.98M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$57.57M | -871.2% |
| FY2024 | Dec 31, 2024 | $7.47M | -94.1% |
| FY2023 | Dec 31, 2023 | $126.22M | -76.4% |
| FY2022 | Dec 31, 2022 | $535.98M | +45.4% |
| FY2021 | Dec 31, 2021 | $368.57M | +142.2% |
| FY2020 | Dec 31, 2020 | $152.19M | +531.1% |
| FY2019 | Dec 31, 2019 | $24.12M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.99M | – |
| Q1 FY2026 | Mar 31, 2026 | $8.67M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.15M | -215.3% |
| Q2 FY2025 | Jun 30, 2025 | -$10.27M | -158.9% |
| Q1 FY2025 | Mar 31, 2025 | -$9.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.64M | -287.9% |
| Q3 FY2024 | Sep 30, 2024 | $13.14M | -7.3% |
| Q2 FY2024 | Jun 30, 2024 | $17.43M | -9.2% |
| Q1 FY2024 | Mar 31, 2024 | -$8.47M | -110.0% |
| Q4 FY2023 | Dec 31, 2023 | $7.79M | -92.2% |
| Q3 FY2023 | Sep 30, 2023 | $14.17M | -87.1% |
| Q2 FY2023 | Jun 30, 2023 | $19.19M | -88.3% |
| Q1 FY2023 | Mar 31, 2023 | $85.07M | -47.6% |
| Q4 FY2022 | Dec 31, 2022 | $99.34M | +69.1% |
| Q3 FY2022 | Sep 30, 2022 | $110.06M | +4.3% |
| Q2 FY2022 | Jun 30, 2022 | $164.28M | -1.0% |
| Q1 FY2022 | Mar 31, 2022 | $162.30M | +323.5% |
| Q4 FY2021 | Dec 31, 2021 | $58.74M | -26.0% |
| Q3 FY2021 | Sep 30, 2021 | $105.56M | +105.3% |
| Q2 FY2021 | Jun 30, 2021 | $165.94M | +1328.7% |
| Q1 FY2021 | Mar 31, 2021 | $38.33M | +294.6% |
| Q4 FY2020 | Dec 31, 2020 | $79.43M | – |
| Q3 FY2020 | Sep 30, 2020 | $51.43M | – |
| Q2 FY2020 | Jun 30, 2020 | $11.62M | – |
| Q1 FY2020 | Mar 31, 2020 | $9.71M | – |
See a number that looks wrong?